Navigation Links
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results Teleconference and Webcast
Date:2/15/2011

EMERYVILLE, Calif., Feb. 15, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss fourth quarter and full year 2010 financial results, on Wednesday, February 23, 2011, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and full year ended December 30, 2010 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3362 and using the passcode 29045749#. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 29045749# approximately one hour after the teleconference concludes. The replay will be available through March 9, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective, next generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
2. ADVENTRX Pharmaceuticals Provides Update on ANX-514
3. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
4. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
5. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
7. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
8. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
10. Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer
11. Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo ... Smart" or "the Company") which develops, markets and ... in China and international ... Disease Diagnosis and Treatment New Progress Forum, co-hosted ... Guangdong Province , Guangdong Provincial People,s ...
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... while the Dow Jones Industrial Average managed to stay in ... markets, which prompted Stock-callers this morning to look at the ... NUVA ), Smith & Nephew PLC (NYSE: ... and Cesca Therapeutics Inc. (NASDAQ: KOOL ). You ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... ... ‘Tis the season for giving! Today, 20 creative teams across the nation ... the Drug Enforcement Administration as part of the National Red Ribbon Week Photo Contest. ... decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be Drug Free,” ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... 2016 , ... The Cronovo Smartwatch, the first on the ... at an affordable price, is now available on the crowdfunding website Kickstarter ... changer” when it comes to the smartwatch. , "With Cronovo, we’ve combined the ...
Breaking Medicine News(10 mins):